Efavirenz acts as a non-nucleoside reverse transcriptase inhibitor for viral infection. Directly binding to catalytic sites, the agent prevents viral synthesis and expansion of load.
Efavirenz belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretroviral agents. It is the biologically active component that interferes with the replication of human immunodeficiency virus (HIV). By binding to the viral reverse transcriptase enzyme, the drug reduces the ability of the virus to copy its genetic material, which helps to keep viral levels lower in the bloodstream. Efavirenz is recognized worldwide as a core element in combination regimens used to treat HIV-1 infection.
In Singapore, efavirenz appears in several fixed-dose combinations and stand-alone tablets that are listed on the Health Sciences Authority (HSA) register. These products are supplied in standard tablet form, commonly at a dosage of 600 mg per tablet. Generic versions are available alongside branded formulations, all containing the same active substance. The tablets are designed for oral use and are packaged with patient information that details the specific strengths and auxiliary ingredients.
The primary indication for efavirenz-containing regimens is the management of HIV-1 infection in adults and adolescents. It is typically paired with two nucleoside reverse transcriptase inhibitors (NRTIs) to form a three-drug combination that targets the virus from multiple angles. The medication is most often chosen for patients who have not previously received antiretroviral therapy, as well as for those whose treatment history supports the use of NNRTI-based regimens. Clinical practice also notes its role in reducing viral load to undetectable levels, which supports immune system recovery.
Efavirenz acts by attaching to a specific site on the HIV reverse transcriptase enzyme, preventing the enzyme from synthesising viral DNA from RNA. This blockage stops the virus from integrating into host cells, thereby limiting the spread of infection. The effect is not permanent; the drug must be present in the bloodstream to maintain its action, which is why consistent daily dosing is essential for therapeutic benefit.
Efavirenz tablets should be stored at room temperature, away from excess moisture and direct sunlight. Because the medication influences viral replication, treatment courses are often long-term, ranging from several months to lifelong therapy, depending on the individual's health plan. Different efavirenz-based products may vary in tablet size, appearance, and auxiliary ingredients, so patients should verify the exact formulation they receive. For details on dosing schedules, administration techniques, and any product-specific instructions, consult the labeling that accompanies the medication.
This article provides an educational overview of efavirenz as an active substance and is not a substitute for professional medical guidance. Individual medicines that contain efavirenz-including the tablets listed for Singapore-may differ in strength, formulation, and specific usage directions. The information presented does not create liability for any clinical decisions. Readers are encouraged to review the labeling on their particular medication and, when needed, seek clarification from a qualified healthcare professional.
